γδ T細胞は,HLAクラスI欠陥を有するがんにおける免疫療法の効果因子である
Natasja L de Vries1,2, Joris van de Haar3,4,5, Vivien Veninga3,4
1Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Nature
|January 11, 2023
まとめ
β2-マイクログローブリン (B2M) 不活性化によるDNA不一致修復欠陥 (MMR-d) がんは,免疫チェックポイントブロック (ICB) に反応する. この反応は γδ T 細胞の浸透の増加と関連しており,これらのがんの免疫療法におけるその役割を示唆している.
科学分野:
- 免疫学
- 腫瘍学
- 遺伝学
背景:
- DNAミスマッチ修復欠陥 (MMR-d) がんは,通常,免疫チェックポイントブロック (ICB) に対する例外的な反応と相関する高いネオアンチゲン負荷を示します.
- HLAクラスI発現に不可欠なβ2-マイクログローブリン (B2M) のゲノム不活性化は,いくつかのMMR-dがんで観察されています.
研究 の 目的:
- B2M不活性化によるMMR-dがんにおける持続的なICB応答のメカニズムを調査する.
- B2M欠乏症の文脈でICB応答に関与する免疫細胞を特定する.
主な方法:
- ゲノムB2M不活性化による21のMMR-dがんの分析
- 腫瘍サンプルにおける γδ T 細胞に焦点を当てた免疫細胞浸透の評価
- γδ T細胞のインビトロ機能検査
- 二重のPD-1とCTLA-4阻害の前と後の腫瘍サンプルを比較する.
主要な成果:
- B2M不活性化によるMMRdがんの95%がICBに対する反応を維持した.
- B2M不活性化とVδ1とVδ3のGδT細胞の浸透の増加との間に強い関連性が見られた.
- PD- 1+ γδ T細胞は,HLAクラスI陰性がん細胞とB2Mノックアウトオルガノイドに対する反応性が強化された.
- ICB治療は,B2M欠乏がんにおける γδ T細胞の頻度を有意に増加させた.
結論:
- γδ T細胞は,HLAクラスI陰性MMR- dがんにおけるICB応答に寄与する.
- これらの発見は,ガン免疫療法,特にB2M欠乏性腫瘍の治療標的としての γδT細胞の可能性を強調しています.
関連する概念動画
Tumor Immunotherapy
621
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
621
Cytotoxic T Cells-mediated Immune Response
1.1K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.1K
T Cell Types and Functions
1.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.2K
T Cell Activation and Clonal Selection
2.5K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
2.5K
Cell-mediated Immune Responses
69.6K
Overview
69.6K
Antigens Involved in Adaptive Immunity
614
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
614


